Advertisement
Advertisement
U.S. markets open in 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

HCW Biologics Inc. (HCWB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7500+0.2100 (+8.27%)
At close: 04:00PM EST
2.5300 -0.22 (-8.00%)
Pre-Market: 07:53AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.5400
Open2.6500
Bid2.5000 x 800
Ask0.0000 x 1000
Day's Range2.5500 - 2.7999
52 Week Range2.3100 - 7.7750
Volume59,087
Avg. Volume3,057,474
Market Cap98.252M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7310
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HCWB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HCW Biologics Inc.
    Daily – Vickers Top Insider Picks for 11/19/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    20 days agoArgus Research
View more
  • GlobeNewswire

    HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

    MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021. “The third quarter of 2021 and recent weeks were an impo

  • Benzinga

    Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results

    Toward the end of trading Thursday, the Dow traded up 0.45% to 35,651.09 while the NASDAQ rose 1.21% to 15,420.51. The S&P also rose, gaining 0.83% to 4,589.40. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 46,597,000 cases with around 761,850 deaths. India confirmed a total of at least 34,231,800 cases and 456,410 deaths, while Brazil reported over 21,766,160 COVID-19 cases with 606,720 deaths. In total, there were at least 245,904,790 cases

  • Benzinga

    Why Did HCW Biologics Shares More Than Double Today?

    Recently listed HCW Biologics Inc (NASDAQ: HCWB) shares almost doubled during premarket Thursday, after FDA signed off Phase 1b trial of its lead candidate in pancreatic cancer. The drug candidate, HCW9218, is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity while simultaneously blocking unwanted immunosuppressive activities. In preclinical studies, HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel agai

Advertisement
Advertisement